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Non-human primates (NHPs) are a very valuable experimental model for diabetes research studies including experimental
pancreatic islet transplantation. In particular NHPs are the recipients of choice to validate pigs as possible source of pancreatic
islets.TheaimofthisstudywastoquantifyglycatedhemoglobinpercentageinNHPsandtoassesswhetherchangesinvaluesreﬂect
the metabolic trends after diabetes induction and islet transplantation. Sera from 15 NHPs were analyzed. 9 NHPs were rendered
diabetic with streptozotocin (STZ), and 3 of them received porcine islet transplants. Hemoglobin A1c (HbA1c) percentage was
measured with an assay based on a latex immunoagglutination inhibition methodology. Whereas diabetes and its duration were
associated with increasing HbA1c levels, postislet transplantation blood glucose normalization was paralleled by a decrease in the
HbA1c percentage. Our data provide evidence that HbA1c is a useful tool to monitor glucose metabolism in NHPs.
1.Introduction
Nonhuman primates (NHPs) do not develop autoimmune
diabetes. However a permanent type 1 diabetes-like status
can be experimentally induced either by total pancre-
atectomy or by chemical destruction of pancreatic β-cells
with streptozotocin (STZ) [1, 2]. Both experimental
approaches allow for the establishment of chronic hyper-
glycemia and low endogenous insulin production in NHPs,
similarly to what it is found in humans with type1 diabetes.
In patients an optimal treatment of diabetes involves control
of glycemia by insulin administrations under haemoglobin
A1c (HbA1c) monitoring [3]. Daily glucose measurements,
even if frequent, do not provide accurate measures of long-
term average blood glucose concentrations. The best method
to assess long-term glycemic control is the measurement
of HbA1c [4]. HbA1c values are important parameters for
physicians and quite helpful to adjust the dose of insulin
and antidiabetic drugs for a better control of the disease [5].
Evidence supporting the translation of HbA1c into glycemic
control and long-term risk assessment of microvascular
complications has been provided by the Diabetes Control
and Complications Trial (DCCT) [3] and the United
Kingdom Prospective Diabetes Study (UPKDS) [6]. The
DCCT and the UKPDS are landmark clinical trials that
compared the eﬀect of intensive glucose-lowering therapies
with conventional blood glucose control on the long-term
risks of complications in patients with type 1 (DCCT)
[3] and type 2 (UKPDS) [6] diabetes. Both of the trials
documented that better glycemic control was associated with
improved clinical outcome.
HbA1c values are strongly correlated with blood glucose
levels and with the risk of developing complications. This
is the reason why we thought it useful to record HbA1c2 Journal of Transplantation
as a parameter to monitor diabetes in NHPs (particularly
in long-term islet graft recipients) as in humans [3]. Even
if species diﬀerences should be taken into consideration,
testing of novel therapeutic approaches in NHPs is one of
the best ways to predict possible eﬀects in humans. Clinical
signs vary, but there is often a gradual progression of the
disease even in NHPs. Traditional tests for the detection of
diabetes mellitus include measurement of fasting plasma
glucose concentrations, measurement of urine glucose
concentrations, oral (OGTT) and IV (IVGTT) glucose
tolerancetests, measurementofurine ketone concentrations,
and measurement of fasting plasma insulin concentrations
[7–11]. Diagnostic criteria are ideally based on the risk of
developing long-term microvascular complications [11–14].
WhileNHPsaretherecipientsofchoicefortestingalternative
sources of pancreatic islets, such tests present challenges in
these animals. These include diﬃculty in sample collection,
necessity for anesthesia during blood drawing with the
potential for drug interactions, multiple confounding factors
(e.g., activity, duration of food withholding, or diet), stress
hyperglycemia attributable to restraint (i.e., catecholamine
release suppressing insulin secretion), and lack of established
reference ranges [15–17].
Objectives of the study reported here were to identify
values for measurement of HbA1c percentage in blood sam-
ples obtained from NHPs (Macaca fascicularis) to determine
whether these percentages varied with respect to glycemic
control after diabetes induction and insulin treatment.
HbA1c measurements were also carried out after pig islet
transplantation in diabetic NHP recipients in an attempt to
assess whether this physiologic variable can be considered
a suitable test to monitor glucose metabolism and provide
a positive feedback after islet transplantation, particularly
in long-term survivors. Even if islet xenotransplantation of
porcine islets in NHPs restores normal blood glucose levels
in diabetic recipients, to date no clear long-term eﬀect has
been fully demonstrated. Glycated hemoglobin percentage
can oﬀer a reliable means to determine the establishment of
euglycemia after xenotransplantation.
2.MaterialsandMethods
2.1. Animals. A total of 15 male Cynomolgus monkeys
(i.e., Macaca fascicularis, Three Spring Scientiﬁc, Perkaise,
PA, USA), 2–4 years old and 2.8–4.9kg (median 3.4kg),
were included in this study; 6 monkeys were nondiabetic,
9 diabetic, and 3 diabetics received islet transplantations.
Catheterswereplacedintothejugularveinandcarotidartery.
GT-DKO pigs (α-1,3-galactosyltransferase double KO pigs)
or hCD46 transgenic pigs (Revivicor, Blacksburg, VA, USA)
were used as sources of pancreata for islet transplantation.
All animal care procedures were in accordance with the
institutional Principles of Laboratory Animal Care (National
Society for Medical Research) and the Guide for the Care
and Use of Laboratory Animals and were approved by the
University of Pittsburgh Animal Care and Use Committee.
2.2. Induction of Diabetes. Diabetes was inducted in 9
monkeys with 125–150mg/kg i.v. of Zanosar Streptozotocin
(Sicor Pharmaceutics, Irvine, CA, USA) in a single dose
[1]. Diabetes was conﬁrmed by persistent hyperglycemia
(>11.1mmol/L on at least two consecutive readings) and
by the need for insulin to prevent ketosis [12]. IVGTTs
(intravenous glucose tolerance test) and ASTs (arginine
stimulationtest)wereperformed7–31days(median12days)
after induction of diabetes. Diabetic monkeys were treated
by continuous i.v. infusion of insulin (Humulin R; Eli Lilly,
Indianapolis, IN, USA) to maintain the blood glucose level
<11.1mmol/L and to prevent the development of ketosis.
Insulin therapy was stopped 1.5h before stimulation tests.
2.3. Metabolic Parameters. Blood glucose (mmol/L) was
measured in whole blood with a portable glucometer
(Freestyle; Abbott Laboratories, Abbott Park, IL, USA).
Serum levels of primate C-peptide (nmol/L) were measured
by radioimmunoassay (Linco Research, St Charles, MO,
USA) using species-speciﬁc antibodies. Aprotinin 0.05kIU/l
(Trasylol; Bayer Pharmaceuticals, West Haven, CT, USA)
was added to the serum as a stabilizing agent. To document
the metabolic status of each monkey before induction
of diabetes, after induction of diabetes, and after islet
transplantation until euthanasia, we recorded mean blood
glucose (mmol/L), the prevalence of blood glucose readings
>11.1mmol/L(%),themeanexogenousinsulinrequirement
(IUkg−1 day−1), and mean porcine (graft) C-peptide levels
[18].
Blood samples for HbA1c testing were collected fasting
every 2–4 weeks before and after induction of diabetes.
Immediately after collection of a sample, blood was trans-
ferred into a tube containing EDTA, which was imme-
diately used for measurement of HbA1c percentages. For
the measurement of speciﬁc HbA1c, an inhibition of latex
agglutination assay is used (HbA1c-speciﬁc mouse mono-
clonal antibody adsorbent onto latex particles, DCA Van-
tage Analyzer, Siemens Healthcare Diagnostics, Deerﬁeld,
IL, USA). An agglutinator (synthetic polymer containing
multiple copies of the immunoreactive portion of HbA1c)
causes agglutination of latex coated with HbA1c speciﬁc
mouse monoclonal antibody. This agglutination reaction
causes increased scattering of light, which is measured as
an increased absorbance at 531nm. HbA1c in whole blood
specimens competes for the limited number of antibody-
latex binding sites causing an inhibition of agglutination
and decreased scattering of light. The decreased scattering is
measured as a decrease absorbance at 531nm. The HbA1c
concentration is then quantiﬁed using a calibration curve
of absorbance versus HbA1c concentration. The percent
HbA1c in the sample is then calculated as follows: %HbA1c
= [HbA1c]/[Total Hemoglobin] × 100.
2.4. Porcine Islet Isolation and Transplantation into Monkeys.
After pancreatectomy in the anesthetized donor pig, islet
isolation was carried out according to a modiﬁcation of
the method described for human islets, optimized for
pigs [19] that involved low enzyme concentration, low
digestion temperature, and minimal mechanical digestion.
Intraportal injection of islets (an average of 40,000–
100,000 islet equivalents/kg body weight) was carried outJournal of Transplantation 3
Table 1: Fasting blood glucose, C-peptide and HbA1c in monkeys and humans.
Cynomolgus monkeys Humans
Blood Glucose (mmol/l) 3.1–4.9 (3.7 ±0.1,n = 31)
a 3.9–5.6 [21]
C-peptide (nmol/l) 0.47–2.93 (1.40 ±0.17,n = 18)
a 0.17–0.66 [20]
HbA1c (%) 3.5–5.0 (4.4 ±0.1,n = 23)
a 4.46–5.52 [22]
Data are ranges, with means ± SE and number of measurements in parameters. Human data were obtained from the literature and were measured in venous
plasma [20–22]. Blood glucose levels are signiﬁcantly lower in monkeys than in humans. C-peptide levels are signiﬁcantly higher in monkeys. There is
statistically diﬀerence regarding HbA1c levels. (Monkeys versus humans, aP<. 05).
under general anesthesia of recipients. Continuous insulin
infusion was restored if blood glucose was consistently
>11.1mmol/L. After induction with antithymocyte globulin,
immunosuppression was maintained with humanized anti-
CD154 monoclonal antibody (ABI 793, Novartis Pharma,
Basel, Switzerland) and mycophenolate mofetil (Roche,
Nutley, NJ, USA) [18].
Anticoagulation/antiaggregation/anti-inﬂammatory
treatment was achieved with heparin or dextran sulfate,
prostacyclin (GlaxoSmithKline, Research Triangle Park, NC,
USA) and aspirin [18]; islet graft function was monitored by
measuring porcine C-peptide.
2.5. Statistical Analysis. A commercially available technical
computing program was used for graphic analyses
(GraphPad Prism 4 for Macintosh GraphPad Software, La
Jolla, CA, USA). Suggested criteria for diabetic classiﬁcation
of subjects were derived from other studies [7, 15] that
involvedtheuseofNHPs.Acommerciallyavailablestatistical
program was used for statistical analyses (GraphPad Prism 4
for Macintosh, GraphPad Software). Experimental data are
presented as means±SE. Human data obtained from the
literature are presented as the range of values or mean of the
published data [20, 21].
3. Results
3.1. Comparison of Metabolic Parameters between Nondiabetic
NHPs and Humans. Fasting HbA1c values measured in
nondiabetic monkeys are presented in Table 1. The data
for healthy monkeys were compared with the human data
from the literature to better characterize similarities and
diﬀerences, even though the comparisons are limited by the
diﬀerence in the testing conditions. For a better characteri-
zation of diﬀerences between monkeys and humans Table 1
also reports fasting blood glucose and C-peptide levels com-
parisons, based on previous reports [18]. Blood glucose in
fasting nondiabetic monkeys ranged from 3.1 to 4.9mmol/l
and was signiﬁcantly lower than the corresponding values in
humans [21] (3.9–5.6mmol/l; P<. 05). Human C-peptide
[20] values were consistently lower than monkey C-peptide
levels (0.47 ± 2.93nmol/l in monkeys versus 0.17–
0.66nmol/linhumans,P<. 05).Furthermore,HbA1cvalues
for nondiabetic healthy monkeys were lower than those in
humans [22], with statistically signiﬁcant diﬀerence (4.4 ±
0.1% in monkeys versus 4.99 ± 0.1% in humans, P<. 05).
3.2. Comparison of Metabolic Parameters between Nondiabetic
and Diabetic NHPs. The HbA1c of nondiabetic monkeys
was compared to that of monkeys that were streptozotocin
(STZ) induced, hyperglycemic, and insulin independent.
The increase in HbA1c levels following diabetes induction
conﬁrmsalsoinNHPsthenotionthatchronicallyhighblood
glucose aﬀects glycation of hemoglobin (Figure 1(a), P<
.05). The diabetic status was characterized using standard
metabolic tests. IVGTT and AST were performed in diabetic
NHPs and compared to nondiabetic controls. As expected,
during the IVGTT the peak of glucose concentration in
diabetic monkeys was signiﬁcantly higher (P<. 05, 2min
after glucose i.v. infusion) than in nondiabetic monkeys
(Figure 1(b)). Thereafter, the glucose levels decreased at a
slower rate in diabetic than nondiabetic animals, as shown
by the lower KG (mean 1.44 ± 0.2mmol−1 min−1, P<. 001).
The C-peptide increase, seen in nondiabetic monkeys, was
absent in diabetic monkeys (Figure 1(c)).
During the AST in nondiabetic monkeys (Figures 1(d)
and 1(e)), blood glucose remained stable while C-peptide
values rose at 2min and then returned at prestimulus value
at 5 minutes. The ACRArg ranged from 0.04 to 1.09nmol/L.
Published data show that human ACRArg is similar to that
in monkeys; however, the absolute basal and stimulated
values are lower in humans than in monkeys (22–23). In
diabetic monkeys during the AST, blood glucose remained
stable at approximately 10.8mmol/L, and C-peptide showed
no response (ARCArg−0.40–0.31nmol/L). In summary, after
STZ treatment, blood glucose levels in monkeys increased
above 10mmol/L, and fasting levels of endogenous C-
peptide declined to values corresponding to 12–18% of
the C-peptide levels before diabetes induction. Insulin was
needed to maintain blood glucose <11.0mmol/L and to
prevent ketosis. Any residual endogenous C-peptide did not
respond to physiological stimuli, as shown by the results of
thedynamictestsandbytheabsenceofacorrelationbetween
endogenous C-peptide and blood glucose levels.
3.3. Comparison of Metabolic Parameters in Diabetic NHPs
before and after Porcine Islet Transplantation. Figure 2 com-
pares the blood glucose proﬁle and HbA1c levels in two
NHPs, during their followup after STZ and (in one case)
islet transplantation. Figure 2(a) shows the blood glucose
levels trend after STZ of monkey M124–08. Despite IV
insulin treatment blood glucose level tended to increase, and
coherently HbA1c values (red dots) also tended to increase
(from a basal pre-STZ value of 4.3% to 8.2% at the end
of followup). Figure 2(b) shows a second monkey (M123-
08) blood glucose proﬁle and HbA1c values prior to and
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Figure 1: Comparison of metabolic parameters between nondiabetic and diabetic monkeys. (a) HbA1c comparison between non diabetic
NHPs and post-STZ diabetic NHPs (∗P<. 05). Mean ± SE of blood glucose levels (b, d) and primate C-peptide levels (c, e) during IVGTT
(b, c) and AST (d, e) in nondiabetic (solid lines) and diabetic (broken lines) monkeys. The primate C-peptide response to physiological
stimuli was completely abolished in diabetic monkeys. This was associated with a prolonged increase in the blood glucose level.
and HbA1c increased after STZ, as also shown in monkey
M124-08, a substantial decrease in blood glucose levels and
a drop in the HbA1c level from 9.9% to 6.5. was recorded
as eﬀect of the islet transplantation. Better physiological
glycemic control was achieved by the islet transplant and was
reﬂected in the improved HbA1c values, testifying to a better
management of the disease.
In this experiment a total of three monkeys were trans-
planted with porcine islets in the liver via the portal vein;
following the transplant, all of them experienced improvedJournal of Transplantation 5
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Figure 2: Blood glucose levels (solid lines) and HbA1c (%) (red dots) in STZ diabetic NHP (a) and STZ diabetic with porcine islet graft
NHP (b). In (a) the HbA1c values are increasing overtime despite exogenous insulin treatment; in (b) the HbA1c value drops after porcine
islet transplant.
metabolic control of glucose. Improvement was deﬁned by
a statistically signiﬁcant drop in between blood glucose
levels (8.87 ± 0.19mmol/L versus 5.28 ± 0.06mmol/L,
P<. 0001) and insulin dose (1.07 ± 0.06IUKg−1 day−1
versus 0.04 ± 0.01IUKg−1 day−1, P<. 0001). Paralleling
theseparameters,astatisticallysigniﬁcantdecreaseinHbA1c
percentage (8.11 ± 0.36 versus 6.16 ± 0.21, P<. 0001) was
found before and after islet transplantation (Figures 3(a),
3(b), 3(c)).
Figure 4 shows a summary of the-HbA1c values com-
paring nondiabetic, diabetic, and islet-transplanted NHPs.
There is a statistically signiﬁcant diﬀerence in HbA1c levels
between nondiabetic and diabetic NHPs and between non-
diabetic and islet-transplanted NHPs (P<. 0001), showing
a trend of improvement of HbA1c values that parallels the
improvement of blood glucose levels, as expected. However,
caution is needed in interpreting these results because of the
short time between samples.
4. Discussion
Glycated hemoglobin (Hb) is produced when a carbohy-
drate, such as glucose, binds to an Hb molecule, such
as HbA0, and undergoes intermolecular transformation to
form a stable glycated ketoamine product [23].
HbA1c is formed via a posttranslational nonenzymatic
attachment of glucose to hemoglobin at a rate dependent
on the ambient blood glucose during the lifespan of the red
blood cells (approximately 120 days in humans). Glycated
Hb percentage represents therefore the integrated value for
average blood glucose concentrations in the preceding 6 to 8
weeks [10]. A number of diﬀerent glycated Hb forms have
been identiﬁed, reﬂecting various attached sugar residues.
These forms include HbA1a (fructose-1,6-diphosphate,
or glucose-6-phosphate), HbA1b (ketamine-linked pyruvic
acid), and HbA1c (glucose) [4]. This last form is the
most commonly tested, constituting approximately 80% of
hemoglobin A1 (HbA1). This hemoglobin is a derivate of
adult hemoglobin (HbA), with monosaccharide (fructose or
glucose)attachments.Instrictchemicalterms,themolecular
structure of HbA1c is N-(1-deoxy)-fructosyl-hemoglobin or
N-(1-deoxyfroctose-1-yl) hemoglobin beta chain. Methods
routinely used for the measurement of glycated Hb percent-
ageseparatethemoleculeonthebasisofitscharge,structure,
or antigenic properties [10]. The most popular methods
rely on the increased negative charge found in the glycated
Hb molecule to distinguish it from its nonglycated form.
These assays include electrophoresis and ion-exchange chro-
matography as by high-performance liquid chromatography
(HPLC). Alternatively, boronate aﬃnity chromatography
separates glycated Hb on the basis of its structure rather
than its charge. In this assay, separation is the result of
carbohydrate moieties on the glycated Hb molecule binding
by condensation to the aﬃnity reagent, di-hydroxyboronate.
This method is speciﬁc for all glycated Hbs, irrespective
of molecular charge or the site of glycation on the Hb
molecule. In addition, it is also able to detect the glycated
portion of Hb in patients with Hb variants such as Hb S,
C, or F. Thus, the term total glycated Hb has been used to
describethistypeofassay.Finally,immunoassays,suchasthe
method we have utilized in this study, have been developed
for the measurement of HbA1c. Monoclonal or polyclonal
antibodies generated against the 6- to 8-amino acid peptide
oftheglycatedaminoterminusoftheβ-globinchainarehere
utilized. Advantages to measure HbA1c percentage with this
technology involve the simplicity of the approach; the need
for one small (only few microliters) blood sample; the fact
that the assay is relatively unaﬀected by recent food intake,
activity, illness, or stress; it still reﬂects glycemic control































































Figure 3: Comparison between blood glucose levels (mmol/L) (a), insulin dose (IUkg−1day−1) (b), and HbA1c (%) (c) in NHPs before and
after porcine islet transplantation. There is a statistically signiﬁcant diﬀerence (∗P<. 0001).
of HbA1c even when pathological hemoglobin variants or
NHPhemoglobinsareinvolved.Unfortunately,therearealso
al o to fd i ﬀerent variables associated with measurement of
glycated Hb percentage that could potentially modify those
values;forexample,processesthatdecreasethemeanlifespan
of RBCs will reduce the availability of Hb for glycation
and, therefore, the percentage of glycated Hb, irrespective
of glucose concentrations. Similarly, conditions that increase
the lifespan of RBCs (e.g., iron deﬁciency) will increase the
amount of glycated Hb. Appropriate validation is therefore
required for experimental animal models such as diabetic
NHP recipients of pig islet xenotransplantations. Reliable
measurement of glycated Hb percentages would be then
useful in determining the eﬃcacy of therapeutic treatments.
Glycated Hb percentages have been measured, only to
a limited degree, in non diabetic, borderline-diabetic, and
conﬁrmed-diabetic NHPs [17, 24–26]. These studies have
involved a relatively low number of species and various
methods. Percentages of HbA1 and HbA1c in nondiabetic
baboons (Papio anubis), measured by use of cation-exchange
chromatography, are approximately half of those found
in humans [24]. It has been suggested that this may be
explained on the basis of diﬀerences in the life-span of RBCs
in humans (100 to 120 days) compared to baboons (30 to 60
days). Variations may also be related to diﬀerences in perme-
abilityofRBCstoglucose[17].Atleast2studies[25,26]ha v e
documentedanincreaseinHbA1cpercentagesinborderline-
diabetic or conﬁrmed-diabetic NHPs. In one group of
Celebes crested macaques (Macaca nigra), the HbA1c value
increased from 2.6% in nondiabetic macaques to 7.9% in
diabetic macaques, as measured by use of electrophoresis
[25].Inadditionmacaqueswithoutoverthyperglycemia,but
with impaired glucose clearance, impaired insulin secretion,
and increased postprandial glucose concentrations, had a
signiﬁcant increase in HbA1c content to 3.5%. Reference
rangesforglycatedHbpercentageshavenotbeendetermined
in many NHPs, but values that increase by ≥10% were
generally considered to be abnormal [7]. Although the
number of animals that were evaluated in our study is
small, also reﬂecting the complexity of the experimental
model, we had the opportunity to use the same technology





















Figure 4: Comparison between HbA1c % levels in nondiabetic,
diabetic, and porcine islet transplanted NHPs. A statistically
signiﬁcant diﬀerence is shown between nondiabetic and diabetic
animalsandnondiabeticandislettransplantedanimals(∗P<. 001).
animals under diﬀerent clinical metabolic conditions: prior
to diabetes induction, as insulin-dependent diabetics, and
after islet transplantation.
T h el e v e l so fH b A 1 co b t a i n e dr e ﬂ e c t e dd i ﬀerent glu-
cose metabolic conditions such as diabetes, and improved
metabolic control following islet transplantation. These
valuescoherentlyrepresenttheexpectedtrendsrelativetothe
experimental metabolic conditions and further validate the
technical approach proposed. By using this simple method
in broader scale studies and employing larger numbers of
animals,abettercorrelationbetweenHbA1clevelsandblood
glucose levels in Cynomolgus monkeys can be achieved.
5. Conclusions
In this study we presented the HbA1c values of nondiabetic
and diabetic NHPs (Macaca Fascicularis), analyzed with
an inhibition of latex agglutination assay (HbA1c-speciﬁc
mouse monoclonal antibody adsorbent onto latex particles).
These values are lower than the ones we ﬁnd in humans
without diabetes and very similar to those in diabetic
patients under insulin treatment, respectively. Total HbA1c
percentage can be measured with a user friendly assay and
provides useful information for control of diabetes mellitus
in NPHs, as is done in human patients, and it could be used
during the standard management of glucose metabolism
in those animals. Our data provide evidence that HbA1c
can be used to monitor diabetes in streptozotocin-diabetic
monkeys and to receive feedbacks on the functionality
of xenogenic islet transplantion, particularly useful during
long-term followups.
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